Ectonucleotidase inhibitors: targeting signaling pathways for therapeutic advancement—an in-depth review

RH Sharafat, A Saeed - Purinergic Signalling, 2024 - Springer
Purinergic Signalling, 2024Springer
Ectonucleotidase inhibitors are a family of pharmacological drugs that, by selectively
targeting ectonucleotidases, are essential in altering purinergic signaling pathways. The
hydrolysis of extracellular nucleotides and nucleosides is carried out by these enzymes,
which include ectonucleoside triphosphate diphosphohydrolases (NTPDases) and ecto-5′-
nucleotidase (CD73). Ectonucleotidase inhibitors can prevent the conversion of ATP and
ADP into adenosine by blocking these enzymes and reduce extracellular adenosine. These …
Abstract
Ectonucleotidase inhibitors are a family of pharmacological drugs that, by selectively targeting ectonucleotidases, are essential in altering purinergic signaling pathways. The hydrolysis of extracellular nucleotides and nucleosides is carried out by these enzymes, which include ectonucleoside triphosphate diphosphohydrolases (NTPDases) and ecto-5′-nucleotidase (CD73). Ectonucleotidase inhibitors can prevent the conversion of ATP and ADP into adenosine by blocking these enzymes and reduce extracellular adenosine. These molecules are essential for purinergic signaling, which is associated with a variability of physiological and pathological processes. By modifying extracellular nucleotide metabolism and improving purinergic signaling regulation, ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitors have the potential to improve cancer treatment, inflammatory management, and immune response modulation. Purinergic signaling is affected by CD73 inhibitors because they prevent AMP from being converted to adenosine. These inhibitors are useful in cancer therapy and immunotherapy because they may improve chemotherapy effectiveness and alter immune responses. Purinergic signaling is controlled by NTPDase inhibitors, which specifically target enzymes involved in extracellular nucleotide breakdown. These inhibitors show promise in reducing immunological responses, thrombosis, and inflammation, perhaps assisting in the treatment of cardiovascular and autoimmune illnesses. Alkaline phosphatase (ALP) inhibitors alter the function of enzymes involved in dephosphorylation reactions, which has an impact on a variety of biological processes. By altering the body’s phosphate levels, these inhibitors may be used to treat diseases including hyperphosphatemia and certain bone problems. This article provides a guide for researchers and clinicians looking to leverage the remedial capability of ectonucleotidase inhibitors in a variety of illness scenarios by illuminating their processes, advantages, and difficulties.
Graphical Abstract
Ectonucleotidases provide a visually appealing way to explore the complex world of extracellular nucleotide metabolism. The abstract’s central visual element is a stylized depiction of the cell membrane, emphasizing the surface-bound ectonucleotidases that are essential for controlling the amounts of extracellular nucleotides. The graphical section goes on to illustrate the wider consequences of ectonucleotidase activity, addressing a number of biological mechanisms, including the regulation of immune response and neurotransmission.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果